HPV (Human Papillomavirus) Study

Darlinghurst Sydney

Did you know that an HPV infection can increase your risk of cervical cancer? Join our study with an investigational treatment that aims to eliminate the virus in infected cells. Find out if this study is right for you.

Description

What to expect

Study details

Ages

25 to 55 years old

Duration

Approximately 30 weeks and there will be 10 in-person clinic visits.

Compensation

Study treatment is provided free of charge and eligible participants will be reimbursed for study visits and reasonable study-related travel expenses.

Eligibility Criteria

You may be eligible to participate if you:

Are a female or person with a cervix, aged 25 to 55.

Have at least one test showing a positive high-risk HPV result (such as HPV 16+, HPV 18+ or HPV 12 Other +) at least 12 months before screening.

Are in generally good health

Other inclusion and exclusion criteria apply.

Locations

Darlinghurst Sydney

Description

Human papillomavirus (HPV) is the most common sexually transmitted infection, and it is estimated that 85% of all women will be infected during their lifetime, often without experiencing symptoms.

Some types of HPV are called high risk HPV as they are associated with an increased risk of cervical cancer which is the fourth most common cancer in women.

Currently, there are no approved therapeutic treatments for high-risk HPV infections.

What to expect

We are conducting a study looking at a new investigational treatment for HPV that aims to eliminate HPV infection in affected cells.

This study has been approved by Central Adelaide Local Health Network Human Research Ethics Committee (CALHN HREC)

Study treatment is provided free of charge and eligible participants will be reimbursed for study visits and reasonable study-related travel expenses.

Apply now

Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.

*You can unsubscribe or opt out at any time.

We collect personal information, such as your name, address and contact details, and details of your medical conditions, that enables us to identify if you may be eligible to participate in a current or future study. On occasion we may also contact people on our database by email, with general news and information relevant to our studies and volunteers. By submitting this form you agree to receive email and text notifications about this and other enrolling studies. You can unsubscribe or opt out at any time. We do not sell, share or distribute our database under any circumstances.

We will collect this information directly from you. If you consent to release of medical records, we will obtain medical information from other agencies on your behalf if these are required for your participation in any clinical study at Momentum Clinical Research.

Security of your information is important. Personal information collected is stored by third party data storage providers. We believe these providers offer safe and secure systems.

All information we collect about you will be treated with confidentiality and can be accessed only by Momentum Clinical Research employees.

By completing our online enrolment form, or any other forms we send you, you agree to us holding your personal details within our databases.

There is no obligation for you to participate in a study that we contact you about. If you decline to participate in a study, that will not affect your eligibility for participation in another study.

Home
Clinical Trials
HPV Study Sydney DH AB

HPV (Human Papillomavirus) Study

Darlinghurst Sydney

Description

What to expect

Study details

Ages

25 to 55 years old

Duration

Approximately 30 weeks and there will be 10 in-person clinic visits.

Compensation

Study treatment is provided free of charge and eligible participants will be reimbursed for study visits and reasonable study-related travel expenses.

Eligibility Criteria

You may be eligible to participate if you:

Are a female or person with a cervix, aged 25 to 55.

Have at least one test showing a positive high-risk HPV result (such as HPV 16+, HPV 18+ or HPV 12 Other +) at least 12 months before screening.

Are in generally good health

Other inclusion and exclusion criteria apply.

Locations

Darlinghurst Sydney

Description

Human papillomavirus (HPV) is the most common sexually transmitted infection, and it is estimated that 85% of all women will be infected during their lifetime, often without experiencing symptoms.

Some types of HPV are called high risk HPV as they are associated with an increased risk of cervical cancer which is the fourth most common cancer in women.

Currently, there are no approved therapeutic treatments for high-risk HPV infections.

What to expect

We are conducting a study looking at a new investigational treatment for HPV that aims to eliminate HPV infection in affected cells.

This study has been approved by Central Adelaide Local Health Network Human Research Ethics Committee (CALHN HREC)

Study treatment is provided free of charge and eligible participants will be reimbursed for study visits and reasonable study-related travel expenses.

Apply now

Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.

*You can unsubscribe or opt out at any time.

We collect personal information, such as your name, address and contact details, and details of your medical conditions, that enables us to identify if you may be eligible to participate in a current or future study. On occasion we may also contact people on our database by email, with general news and information relevant to our studies and volunteers. By submitting this form you agree to receive email and text notifications about this and other enrolling studies. You can unsubscribe or opt out at any time. We do not sell, share or distribute our database under any circumstances.

We will collect this information directly from you. If you consent to release of medical records, we will obtain medical information from other agencies on your behalf if these are required for your participation in any clinical study at Momentum Clinical Research.

Security of your information is important. Personal information collected is stored by third party data storage providers. We believe these providers offer safe and secure systems.

All information we collect about you will be treated with confidentiality and can be accessed only by Momentum Clinical Research employees.

By completing our online enrolment form, or any other forms we send you, you agree to us holding your personal details within our databases.

There is no obligation for you to participate in a study that we contact you about. If you decline to participate in a study, that will not affect your eligibility for participation in another study.